Nasus Pharma Ltd.

Nasus Pharma Ltd. is a specialized pharmaceutical firm currently advancing through clinical trials. Their primary focus is on developing innovative nasal medications designed to swiftly address critical emergency health situations. These urgent conditions include severe allergic reactions, such as anaphylaxis, and instances of opioid overdose. At the forefront of their product pipeline are two key treatments: NS002, an intranasal epinephrine powder spray engineered to rapidly combat type 1 severe allergies and anaphylaxis; and NS001, a naloxone powder delivered via a nasal spray, intended to reverse the effects of opioid overdose. A core advantage of their methodology is the utilization of a unique powder-based intranasal delivery system, which ensures exceptionally quick absorption of the medication into the bloodstream.